Carna Biosciences, Inc. Logo

Carna Biosciences, Inc.

Develops kinase inhibitor drugs for oncology/autoimmune diseases & offers discovery support services.

4572 | T

Overview

Corporate Details

ISIN(s):
JP3220550002
LEI:
Country:
Japan
Address:
神戸市中央区港島南町一丁目5番5号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Carna Biosciences, Inc. is a clinical-stage biopharmaceutical company founded in 2003, specializing in the discovery and development of innovative kinase inhibitor drugs. The company focuses on creating small molecule therapies to address unmet medical needs in oncology, autoimmune diseases, and neurodegenerative disorders. Carna Biosciences operates a dual business model: advancing its proprietary drug pipeline for out-licensing and providing comprehensive drug discovery support services. These services include the manufacturing of kinase proteins, as well as offering profiling, screening, and assay development to support pharmaceutical and biotechnology research globally. The company leverages its deep expertise in kinase biology to develop novel therapeutic candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-11 07:45
Registration Form
訂正有価証券届出書(組込方式)
Japanese 347.4 KB
2025-09-12 08:46
Registration Form
訂正有価証券届出書(組込方式)
Japanese 325.6 KB
2025-08-07 02:46
Registration Form
訂正有価証券届出書(組込方式)
Japanese 243.9 KB
2025-08-07 02:45
Registration Form
訂正有価証券届出書(組込方式)
Japanese 244.0 KB
2025-08-07 02:43
Interim Report
確認書
Japanese 8.8 KB
2025-08-07 02:42
Interim Report
半期報告書-第23期(2025/01/01-2025/12/31)
Japanese 358.3 KB
2025-07-11 08:47
Registration Form
有価証券届出書(組込方式)
Japanese 393.6 KB
2025-07-11 08:46
Registration Form
有価証券届出書(組込方式)
Japanese 393.6 KB
2025-07-11 08:45
Registration Form
有価証券届出書(組込方式)
Japanese 392.8 KB
2025-03-28 02:41
Regulatory News Service
臨時報告書
Japanese 28.5 KB
2025-03-26 02:11
Governance Information
内部統制報告書-第22期(2024/01/01-2024/12/31)
Japanese 24.5 KB
2025-03-26 02:10
Registration Form
確認書
Japanese 8.7 KB
2025-03-26 02:08
Annual Report
有価証券報告書-第22期(2024/01/01-2024/12/31)
Japanese 1.3 MB
2024-09-25 08:39
Share Issue/Capital Change
臨時報告書
Japanese 122.5 KB
2024-08-08 02:51
Report Publication Announcement
確認書
Japanese 8.7 KB

Automate Your Workflow. Get a real-time feed of all Carna Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Carna Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Carna Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.